JP2013525332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525332A5 JP2013525332A5 JP2013505469A JP2013505469A JP2013525332A5 JP 2013525332 A5 JP2013525332 A5 JP 2013525332A5 JP 2013505469 A JP2013505469 A JP 2013505469A JP 2013505469 A JP2013505469 A JP 2013505469A JP 2013525332 A5 JP2013525332 A5 JP 2013525332A5
- Authority
- JP
- Japan
- Prior art keywords
- strand
- sequence
- composition
- nucleotides
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32737910P | 2010-04-23 | 2010-04-23 | |
| US61/327,379 | 2010-04-23 | ||
| US33339810P | 2010-05-11 | 2010-05-11 | |
| US61/333,398 | 2010-05-11 | ||
| PCT/EP2011/056299 WO2011131707A1 (en) | 2010-04-23 | 2011-04-20 | ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014085797A Division JP5976032B2 (ja) | 2010-04-23 | 2014-04-17 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525332A JP2013525332A (ja) | 2013-06-20 |
| JP2013525332A5 true JP2013525332A5 (cg-RX-API-DMAC7.html) | 2014-06-05 |
| JP5857378B2 JP5857378B2 (ja) | 2016-02-10 |
Family
ID=44227799
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505469A Expired - Fee Related JP5857378B2 (ja) | 2010-04-23 | 2011-04-20 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| JP2014085797A Expired - Fee Related JP5976032B2 (ja) | 2010-04-23 | 2014-04-17 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| JP2016141325A Expired - Fee Related JP6290316B2 (ja) | 2010-04-23 | 2016-07-19 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| JP2018019887A Expired - Fee Related JP6577073B2 (ja) | 2010-04-23 | 2018-02-07 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| JP2019150816A Pending JP2019214604A (ja) | 2010-04-23 | 2019-08-21 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| JP2021165417A Pending JP2022003089A (ja) | 2010-04-23 | 2021-10-07 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014085797A Expired - Fee Related JP5976032B2 (ja) | 2010-04-23 | 2014-04-17 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| JP2016141325A Expired - Fee Related JP6290316B2 (ja) | 2010-04-23 | 2016-07-19 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| JP2018019887A Expired - Fee Related JP6577073B2 (ja) | 2010-04-23 | 2018-02-07 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| JP2019150816A Pending JP2019214604A (ja) | 2010-04-23 | 2019-08-21 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| JP2021165417A Pending JP2022003089A (ja) | 2010-04-23 | 2021-10-07 | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (10) | US8344127B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3061824B1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP5857378B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR20190122893A (cg-RX-API-DMAC7.html) |
| CN (2) | CN102985544A (cg-RX-API-DMAC7.html) |
| AR (1) | AR081082A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011244335B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012027080A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3098080A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2561077T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA034363B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2574204T3 (cg-RX-API-DMAC7.html) |
| MX (2) | MX350595B (cg-RX-API-DMAC7.html) |
| TW (1) | TWI434692B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011131707A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190122893A (ko) | 2010-04-23 | 2019-10-30 | 애로우헤드 파마슈티컬스 인코포레이티드 | 베타-ＥＮａＣ-관련 질환을 치료하기 위한 유기 조성물 |
| CN102397279B (zh) * | 2011-11-18 | 2012-10-31 | 新乡医学院 | 无羁萜-3β-醇在制备抗血管性痴呆的药物中的应用 |
| RS54944B1 (sr) | 2012-07-12 | 2016-11-30 | Proqr Therapeutics Ii Bv | Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji |
| CN106232073B (zh) | 2014-02-28 | 2020-11-03 | 阿坦斯医疗保健产品公司 | 具有多层折叠吸收芯的吸收性用品 |
| CN109475552B (zh) * | 2016-08-09 | 2022-04-05 | 上海药苑生物科技有限公司 | 用于食欲控制和体重管理的方法和组合物 |
| WO2018112229A1 (en) | 2016-12-14 | 2018-06-21 | Eam Corporation | Absorbent laminates, absorbent cores and disposable articles utilizing the absorbent laminates, and related methods |
| WO2019231926A1 (en) | 2018-05-28 | 2019-12-05 | Attends Healthcare Products, Inc. | Dryness layer laminate for absorbent articles |
| CN109364248B (zh) * | 2018-10-16 | 2021-05-18 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
| TW202130809A (zh) * | 2019-10-29 | 2021-08-16 | 美商愛羅海德製藥公司 | 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法 |
| WO2021188906A1 (en) * | 2020-03-19 | 2021-09-23 | Nature's Toolbox, Inc. | Novel mrna-based covid-19 multi-valent vaccine and methods of scaled production of the same |
| CN114149492A (zh) * | 2020-08-21 | 2022-03-08 | 中国人民解放军军事科学院军事医学研究院 | 一种用于预防甲型流感病毒感染的HA-mRNA疫苗 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696561B1 (en) | 1909-07-09 | 2004-02-24 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL151781A0 (en) | 2000-03-16 | 2003-04-10 | Genetica Inc | Methods and compositions for rna interference |
| DE60140676D1 (de) | 2000-03-30 | 2010-01-14 | Massachusetts Inst Technology | Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| WO2003070910A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| ATE468861T1 (de) | 2001-08-16 | 2010-06-15 | Univ Pennsylvania | Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung |
| AU2002364612A1 (en) | 2001-12-31 | 2003-07-24 | Algos Therapeutics, Inc. | METHODS AND MATERIALS FOR MODULATING ENaC-BETA |
| ES2354607T3 (es) | 2002-06-28 | 2011-03-16 | Protiva Biotherapeutics Inc. | Procedimiento y aparato para producir liposomas. |
| CA2500468A1 (en) | 2002-09-28 | 2004-04-08 | Massachussets Institute Of Technology | Influenza therapeutic |
| US8090542B2 (en) * | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| EP1585756B1 (en) | 2002-11-26 | 2010-04-21 | University of Massachusetts | Delivery of sirnas |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| JP2007528712A (ja) * | 2003-07-10 | 2007-10-18 | セノミックス、インコーポレイテッド | ヒトＥＮａＣを発現する卵母細胞を用いた改良された電気生理学的アッセイ及び膜電位リポーター色素を用いたアッセイにおけるＥＮａＣ相乗剤の効果を向上させるためのフェナミルの使用 |
| JP4951338B2 (ja) | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質に封入された干渉ｒｎａ |
| WO2005021749A1 (en) | 2003-08-28 | 2005-03-10 | Novartis Ag | Interfering rna duplex having blunt-ends and 3’-modifications |
| CN101052717A (zh) | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| ATE533358T1 (de) | 2005-09-16 | 2011-12-15 | Devgen Nv | Verfahren zum kontrollieren von schädlingen mittels rnai |
| CA2628300C (en) | 2005-11-02 | 2018-04-17 | Protiva Biotherapeutics, Inc. | Modified sirna molecules and uses thereof |
| US7389426B2 (en) | 2005-11-29 | 2008-06-17 | Research In Motion Limited | Mobile software terminal identifier |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| NZ580712A (en) | 2007-05-22 | 2011-12-22 | Marina Biotech Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers |
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| EP2238251B1 (en) | 2007-12-27 | 2015-02-11 | Protiva Biotherapeutics Inc. | Silencing of polo-like kinase expression using interfering rna |
| KR20190122893A (ko) | 2010-04-23 | 2019-10-30 | 애로우헤드 파마슈티컬스 인코포레이티드 | 베타-ＥＮａＣ-관련 질환을 치료하기 위한 유기 조성물 |
-
2011
- 2011-04-20 KR KR1020197031212A patent/KR20190122893A/ko not_active Ceased
- 2011-04-20 MX MX2012012355A patent/MX350595B/es active IP Right Grant
- 2011-04-20 AR ARP110101377A patent/AR081082A1/es unknown
- 2011-04-20 KR KR1020187008466A patent/KR20180033606A/ko not_active Ceased
- 2011-04-20 EP EP16163880.4A patent/EP3061824B1/en active Active
- 2011-04-20 BR BR112012027080A patent/BR112012027080A2/pt not_active Application Discontinuation
- 2011-04-20 AU AU2011244335A patent/AU2011244335B2/en not_active Ceased
- 2011-04-20 CA CA3098080A patent/CA3098080A1/en active Pending
- 2011-04-20 WO PCT/EP2011/056299 patent/WO2011131707A1/en not_active Ceased
- 2011-04-20 EA EA201201457A patent/EA034363B1/ru not_active IP Right Cessation
- 2011-04-20 MX MX2017011441A patent/MX383583B/es unknown
- 2011-04-20 DK DK11715243.9T patent/DK2561077T3/en active
- 2011-04-20 ES ES11715243.9T patent/ES2574204T3/es active Active
- 2011-04-20 EP EP11715243.9A patent/EP2561077B1/en active Active
- 2011-04-20 US US13/090,580 patent/US8344127B2/en not_active Expired - Fee Related
- 2011-04-20 CN CN201180030997XA patent/CN102985544A/zh active Pending
- 2011-04-20 KR KR1020127030568A patent/KR20130051954A/ko not_active Ceased
- 2011-04-20 EP EP18190981.3A patent/EP3431604A1/en active Pending
- 2011-04-20 CA CA2797051A patent/CA2797051C/en active Active
- 2011-04-20 CN CN201711213535.7A patent/CN107929306B/zh active Active
- 2011-04-20 KR KR1020227000366A patent/KR20220008383A/ko not_active Ceased
- 2011-04-20 JP JP2013505469A patent/JP5857378B2/ja not_active Expired - Fee Related
- 2011-04-22 TW TW100114186A patent/TWI434692B/zh not_active IP Right Cessation
-
2012
- 2012-01-23 US US13/355,879 patent/US8344129B2/en not_active Expired - Fee Related
- 2012-01-23 US US13/355,930 patent/US8344131B2/en not_active Expired - Fee Related
- 2012-01-23 US US13/355,903 patent/US8344130B2/en not_active Expired - Fee Related
- 2012-09-13 US US13/614,836 patent/US8598335B2/en not_active Expired - Fee Related
-
2013
- 2013-10-01 US US14/042,924 patent/US9080175B2/en active Active
-
2014
- 2014-04-17 JP JP2014085797A patent/JP5976032B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-28 US US14/723,555 patent/US9376683B2/en active Active
-
2016
- 2016-05-27 US US15/166,576 patent/US9752152B2/en not_active Expired - Fee Related
- 2016-07-19 JP JP2016141325A patent/JP6290316B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-27 US US15/661,132 patent/US10081811B2/en active Active
-
2018
- 2018-02-07 JP JP2018019887A patent/JP6577073B2/ja not_active Expired - Fee Related
- 2018-08-20 US US16/105,522 patent/US10550391B2/en active Active
-
2019
- 2019-08-21 JP JP2019150816A patent/JP2019214604A/ja active Pending
-
2021
- 2021-10-07 JP JP2021165417A patent/JP2022003089A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525332A5 (cg-RX-API-DMAC7.html) | ||
| JP2013514321A5 (cg-RX-API-DMAC7.html) | ||
| JP2014525435A5 (cg-RX-API-DMAC7.html) | ||
| JP2016511256A5 (cg-RX-API-DMAC7.html) | ||
| Ezzat et al. | Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides | |
| US20210238601A1 (en) | Oligonucleotide Conjugates | |
| Ma et al. | Recent advances of discrete coordination complexes and coordination polymers in drug delivery | |
| Godinho et al. | Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: Focus on Huntington’s disease | |
| JP2024028909A (ja) | ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物 | |
| JP2015503608A5 (cg-RX-API-DMAC7.html) | ||
| Huang et al. | Orally targeted galactosylated chitosan poly (lactic-co-glycolic acid) nanoparticles loaded with TNF-ɑ siRNA provide a novel strategy for the experimental treatment of ulcerative colitis | |
| AU2015252841B2 (en) | Compositions and methods for modulating growth hormone receptor expression | |
| WO2009120887A3 (en) | Compositions and methods for tissue-specific rnai delivery in vivo | |
| JP2012528857A5 (cg-RX-API-DMAC7.html) | ||
| JP2021533762A (ja) | Ｓｎｐを標的化する修飾オリゴヌクレオチド | |
| JP2017518045A5 (cg-RX-API-DMAC7.html) | ||
| JP2016116520A5 (cg-RX-API-DMAC7.html) | ||
| JP2013516190A5 (cg-RX-API-DMAC7.html) | ||
| JP2015500835A5 (cg-RX-API-DMAC7.html) | ||
| JP2009517048A5 (cg-RX-API-DMAC7.html) | ||
| JP2007533323A (ja) | 哺乳類の細胞における遺伝子発現を調節するための、二本鎖ｒｎａまたは二本鎖ハイブリッド核酸の送達を増強するための方法および組成物 | |
| JP2016523564A5 (cg-RX-API-DMAC7.html) | ||
| JP2015517806A5 (cg-RX-API-DMAC7.html) | ||
| JP2011530537A5 (cg-RX-API-DMAC7.html) | ||
| JP2015523854A5 (cg-RX-API-DMAC7.html) |